NO20081654L - Stabiliserte GLP-1-analoger - Google Patents
Stabiliserte GLP-1-analogerInfo
- Publication number
- NO20081654L NO20081654L NO20081654A NO20081654A NO20081654L NO 20081654 L NO20081654 L NO 20081654L NO 20081654 A NO20081654 A NO 20081654A NO 20081654 A NO20081654 A NO 20081654A NO 20081654 L NO20081654 L NO 20081654L
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- glp
- analogs
- base sequence
- side groups
- Prior art date
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 6
- 150000001413 amino acids Chemical class 0.000 abstract 9
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 3
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71532205P | 2005-09-08 | 2005-09-08 | |
| PCT/US2006/034685 WO2007030519A2 (en) | 2005-09-08 | 2006-09-07 | Stabilized glp-1 analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081654L true NO20081654L (no) | 2008-04-03 |
Family
ID=37836409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081654A NO20081654L (no) | 2005-09-08 | 2008-04-03 | Stabiliserte GLP-1-analoger |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8318668B2 (zh) |
| EP (2) | EP2497781A1 (zh) |
| JP (1) | JP2009507844A (zh) |
| KR (1) | KR20080052649A (zh) |
| CN (1) | CN101262874A (zh) |
| AU (1) | AU2006287562B2 (zh) |
| BR (1) | BRPI0615573A2 (zh) |
| CA (1) | CA2621699A1 (zh) |
| IL (1) | IL189996A0 (zh) |
| NO (1) | NO20081654L (zh) |
| WO (1) | WO2007030519A2 (zh) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7259234B2 (en) * | 2003-05-15 | 2007-08-21 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| CA2726903A1 (en) * | 2008-06-03 | 2009-12-10 | Trustees Of Tufts College | Long-acting glp-1 derivatives, and methods of treating cardiac dysfunction |
| ES2661228T3 (es) | 2010-05-13 | 2018-03-28 | Indiana University Research And Technology Corporation | Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona |
| BR112012029248B1 (pt) * | 2010-05-17 | 2021-09-28 | Betta Pharmaceuticals Co., Ltd | Análogo de glp-1 de fórmula i ou a sua composição, análogo de glp-1 de fórmula viii ou um sal farmaceuticamente aceitável ou a composição do mesmo, composição farmacêutica e uso de um composto |
| WO2011163012A2 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| KR20140097151A (ko) | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루코코르티코이드 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| EP2630965A1 (en) * | 2012-02-24 | 2013-08-28 | Curatis Pharma GmbH | A polypeptide for the protection from neurodegeneration in patients with amyotrophic lateral sclerosis (ALS) |
| WO2015081891A1 (en) | 2013-12-06 | 2015-06-11 | Baikang (Suzhou) Co., Ltd | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| JP5910901B1 (ja) * | 2015-03-27 | 2016-04-27 | 株式会社東洋新薬 | Ｇｌｐ−１分泌促進剤 |
| TWI726889B (zh) * | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| EP3774862B1 (en) | 2018-04-05 | 2022-06-08 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
| EP3875476A4 (en) * | 2018-10-30 | 2022-08-24 | Jianning Liu | GLP-1 POLYPEPTIDE WITH GLP-1 RECEPTOR AGONIST ACTIVITY AND USES THEREOF |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| EP0636032A1 (en) | 1992-03-25 | 1995-02-01 | Mallinckrodt Medical, Inc. | Method of intraoperatively detecting and locating tumoral tissues |
| EP0678018B1 (en) | 1993-01-06 | 2003-04-09 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| US6890905B2 (en) * | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
| AU2002317599B2 (en) * | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
| JP2005508895A (ja) * | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１および基礎インスリンの予備混合物 |
| CA2463908A1 (en) * | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US7238671B2 (en) * | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US7259234B2 (en) * | 2003-05-15 | 2007-08-21 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
-
2006
- 2006-09-07 CN CNA2006800331050A patent/CN101262874A/zh active Pending
- 2006-09-07 EP EP11194831A patent/EP2497781A1/en not_active Withdrawn
- 2006-09-07 CA CA002621699A patent/CA2621699A1/en not_active Abandoned
- 2006-09-07 KR KR1020087008178A patent/KR20080052649A/ko not_active Application Discontinuation
- 2006-09-07 EP EP06814219A patent/EP1940438A4/en not_active Withdrawn
- 2006-09-07 WO PCT/US2006/034685 patent/WO2007030519A2/en active Application Filing
- 2006-09-07 AU AU2006287562A patent/AU2006287562B2/en not_active Ceased
- 2006-09-07 BR BRPI0615573-1A patent/BRPI0615573A2/pt not_active Application Discontinuation
- 2006-09-07 US US12/066,324 patent/US8318668B2/en active Active
- 2006-09-07 JP JP2008530161A patent/JP2009507844A/ja not_active Ceased
-
2008
- 2008-03-06 IL IL189996A patent/IL189996A0/en unknown
- 2008-04-03 NO NO20081654A patent/NO20081654L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20090306338A1 (en) | 2009-12-10 |
| KR20080052649A (ko) | 2008-06-11 |
| EP1940438A2 (en) | 2008-07-09 |
| AU2006287562A1 (en) | 2007-03-15 |
| WO2007030519A3 (en) | 2007-11-29 |
| IL189996A0 (en) | 2008-08-07 |
| BRPI0615573A2 (pt) | 2011-05-24 |
| EP1940438A4 (en) | 2009-10-21 |
| EP2497781A1 (en) | 2012-09-12 |
| WO2007030519A2 (en) | 2007-03-15 |
| JP2009507844A (ja) | 2009-02-26 |
| CN101262874A (zh) | 2008-09-10 |
| US8318668B2 (en) | 2012-11-27 |
| AU2006287562B2 (en) | 2012-05-10 |
| CA2621699A1 (en) | 2007-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081654L (no) | Stabiliserte GLP-1-analoger | |
| DE602005020165D1 (de) | Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin | |
| DK1877435T4 (da) | Glucagon-lignende-peptid-2 (glp-2)-analoger | |
| CY1110397T1 (el) | Πολυπεπτιδιο που εχει βελτιωμενη δραστικοτητα αποαμινασης κυτοσινης | |
| PE20130615A1 (es) | Polipeptidos del receptor de activina variante y uso de los mismos | |
| EA200901108A1 (ru) | Соагонисты глюкагоновых/glp-1-рецепторов | |
| RU2010147076A (ru) | Аналоги инсулина специфичные к изоформам | |
| NO20061026L (no) | Nye insulinderivater | |
| EA201170878A1 (ru) | Полипептиды с ксиланазной активностью | |
| WO2007115837B1 (en) | Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule | |
| DK2231860T3 (da) | Polypeptid afledt protein A og i stand til at binde PDGF | |
| GEP20115196B (en) | Neublastin variants | |
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| BR0309491A (pt) | Composição de vacina, composição imunogênica, utilização de uma proteìna e7 e anticorpos neutralizantes | |
| ATE538806T1 (de) | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren | |
| BRPI0715331B8 (pt) | polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo | |
| NO20083576L (no) | Peptider av regulatoriske eller hjelpeproteiner av HIV, samt sammensetninger og anvendelser derav | |
| DE602005025989D1 (de) | Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden | |
| MX2015016560A (es) | Proteina analgesica aislada de la secrecion de la rana trachycephalous venulosus. | |
| NO20082864L (no) | Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav | |
| MX2021013702A (es) | Subunidad s2 modificada de la proteina de espicula de coronavirus. | |
| CA2722618A1 (en) | Method of treating degenerative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |